ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,043.63
-0.06%
US Tech 100
20,624.40
0.06%
Dow Jones
44,699.57
-0.18%
Brent Oil
73.675
2.48%
Bitcoin
94,993.90
-0.90%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) Quote

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
2.675
-0.405
( -13.15% )
Updated: 14:01:37
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.675
Bid
2.67
Ask
2.68
Volume
3,305,423
2.625 Day's Range 3.1119
1.19 52 Week Range 4.32
Market Cap
548.223M
Previous Close
3.08
Open
3.05
Last Trade
100
@
2.6737
(average)
Last Trade Time
14:01:56
Financial Volume
$ 9,237,218
VWAP
2.7946
Average Volume (3m)
3,995,617
Shares Outstanding
204,943,306
Dividend Yield
-
PE Ratio
-5.00
Earnings Per Share (EPS)
-0.54
Revenue
15.45M
Net Profit
-111.57M

About Taysha Gene Therapies Inc

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.tayshagtx.com
Headquarters
Dover, Delaware, USA
Founded
-
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was $3.08. Over the last year, Taysha Gene Therapies shares have traded in a share price range of $ 1.19 to $ 4.32.

Taysha Gene Therapies currently has 204,943,306 shares outstanding. The market capitalization of Taysha Gene Therapies is $631.23 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -5.00.

Ask ADVFN Intelligence (AI)

TSHA Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 13 2024
Edgar (US Regulatory)

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two...

November 13 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 08 2024
Edgar (US Regulatory)

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

November 06 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...

November 01 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

October 22 2024
Edgar (US Regulatory)

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and...

October 22 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

October 04 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...

September 26 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

September 06 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.205-7.118055555562.883.312.62555650083.02953783CS
41.345101.1278195491.333.311.1982020762.19687574CS
120.39517.32456140352.283.311.1939956172.10896575CS
26-0.775-22.46376811593.454.321.1931283002.31351799CS
520.77540.78947368421.94.321.1927227062.36037634CS
156-10.595-79.841748304413.2715.340.517992072.42534309CS
260-19.575-87.977528089922.2533.840.513220343.01997793CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CTNTCheetah Net Supply Chain Service Inc
$ 5.318
(184.39%)
107.59M
ZJKZJK Industrial Company Ltd
$ 14.37
(126.66%)
20.59M
GWAVGreenwave Technology Solutions Inc
$ 0.6041
(65.51%)
404.06M
JANXJanux Therapeutics Inc
$ 62.10
(54.55%)
5.33M
JYDJayud Global Logistics Ltd
$ 1.03
(53.71%)
9.42M
REVBRevelation Biosciences Inc
$ 0.5649
(-40.53%)
3.88M
OMEXOdyssey Marine Exploration Inc
$ 0.48335
(-35.14%)
3.55M
STSSSharps Technology Inc
$ 2.2308
(-33.48%)
380.92k
GELSGelteq Ltd
$ 2.6491
(-30.66%)
225.23k
MOBXMobix Labs Inc
$ 1.0022
(-28.42%)
1.23M
GWAVGreenwave Technology Solutions Inc
$ 0.6035
(65.34%)
404.24M
SMCISuper Micro Computer Inc
$ 41.22
(-1.86%)
171.03M
CTNTCheetah Net Supply Chain Service Inc
$ 5.3101
(183.96%)
109.14M
CHRSCoherus BioSciences Inc
$ 1.785
(30.29%)
104.76M
NVDANVIDIA Corporation
$ 139.3338
(0.51%)
102.78M

TSHA Discussion

View Posts
glenn1919 glenn1919 1 week ago
TSHA..............https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 weeks ago
TSHA...$2.58...Off the $2.10 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 85

Tuesday, November 12, 2024 3:56:56 PM

Post#
89
of 90
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
glenn1919 glenn1919 3 weeks ago
TSHA............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 weeks ago
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
zendeli1 zendeli1 3 weeks ago
restart soon
👍️0
glenn1919 glenn1919 3 weeks ago
TSHA....................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 weeks ago
TSHA.................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 weeks ago
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
nsomniyak nsomniyak 3 weeks ago
I sent an email to TSHA IR on 11/5 asking if they could explain the sharp drop (at that time) and high volume in the stock. I did not receive an answer.
👍️0
nsomniyak nsomniyak 3 weeks ago
Premiums were high all last week and today on TSHA call options. Volume in the common has been high as well.
👍️0
Pip611 Pip611 3 weeks ago
I was thinking the same thing, it started to pop in the afternoon and now it took off after hours
👍️0
nsomniyak nsomniyak 3 weeks ago
What is going on with TSHA in the AH today? Up sharply - now 2.10
👍️0
Monksdream Monksdream 1 month ago
TSHA under $3
👍️0
Monksdream Monksdream 4 months ago
TSHA under $3
👍️0
TechandBio TechandBio 5 months ago
Started buying shares last year at .77 Riding the houses money now and sold three quarters of my shares at $4.00 range when I saw the double top formation come into play I can see this going to $8.00-$10.00 only on a buyout in the next year. Risky with only a handful of patients dosed and the competition for Rhett but a cunning bet with the management at TSHA. now.
CEO and CMO are best in class. Not a core position but glad I'm in with a few. I hope they have a remedy for these poor kids with Rhett.

$TSHA
👍️0
nsomniyak nsomniyak 5 months ago
If these are senior people in prominent management or technical roles it is pretty standard for them to be granted options as part of their compensation package. They vest over 4 years, so it is not an outright giveaway.

Additionally, since these are NEW employees, by definition they have not manipulated the stock down to get a lower option strike price.

I am fine with this very normal comp package.
👍️ 1
ErnieBilco ErnieBilco 5 months ago
I'm sorry but granting options to NEW employees is absurd - they shouldn't be entitled to stock options UNTIL their one year on the job.

No wonder why this has trouble making gains for shareholders whom the employees actually work for.
👍️0
LegendaryNomad22 LegendaryNomad22 6 months ago
Weird. Both TSHA and NGNE have gene therapy candidates for Rett and both of them tanked today, despite sharing strong interim results. There's an International Rett Syndrome Foundation meeting today and tomorrow, so I wonder if something happened there to take the wind out of the gene therapy treatment class. Anyone have any knowledge here?
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
Diluted on news
👍️0
Pip611 Pip611 6 months ago
Ouch - what happen?
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA...GAPPING
👍️0
Tiger Money Tiger Money 6 months ago
Yes, no sorry, didn’t mean to imply that. I was asking if you have other bio names you have on your radar (obviously know about this and Huma). Thanks
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
chart has nothing to do with what sector!!
👍️0
Tiger Money Tiger Money 6 months ago
You have the bios nailed down! Any I should put on my radar? As always, thank you as I sincerely appreciate your help and knowledge. Thanks!
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA BREAK OUT
👍️0
Monksdream Monksdream 6 months ago
TSHA new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA...HERES 4 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA...READY FOR 4
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA...BIO BEAST BREAKING HEWRE CHAINS
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA HERE WE GO ON THE BREAK OUT!!
👍️0
glenn1919 glenn1919 6 months ago
TSHA......................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA HERE COMES THE BREAK
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TSHA...NEXT BIO READY TO BEAST!
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.
👍️0
Monksdream Monksdream 6 months ago
TSHA under $5
👍️0
glenn1919 glenn1919 8 months ago
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 11 months ago
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 1 year ago
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0
bikaver bikaver 1 year ago
TSHA.....Definitely headed in the right direction now. A couple more days of downward momo would be great.
👍️0
make it happen make it happen 1 year ago
Cannacord Genuity and Truist Securities both lowered there price targets, never a good thing...
👍️0
make it happen make it happen 1 year ago
Think it's about there. I believe we flush under $3.00 and don't come back to the this price per share PPS till R/S. A ways away but see it happening. JMHO
👍️0
bikaver bikaver 1 year ago
TSHA.....kicking my butt.....next week is make or break!
👍️0

Your Recent History

NASDAQ
TSHA
Taysha Gene Therapies
LSE
CTEC
Convatec
DOWI
DJIETEC
DJ Islamic Market World ...
NASDAQ
AMID
Argent Mid Cap ETF
LSE
CASP
Caspian Sunrise
DOWI
DJBICEET
DJ Brookfield Glbl Infra...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved